0000919574-22-004056.txt : 20220706
0000919574-22-004056.hdr.sgml : 20220706
20220706161534
ACCESSION NUMBER: 0000919574-22-004056
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220701
FILED AS OF DATE: 20220706
DATE AS OF CHANGE: 20220706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BRADSHER NEAL C
CENTRAL INDEX KEY: 0001278388
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12830
FILM NUMBER: 221068868
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc.
CENTRAL INDEX KEY: 0000876343
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943127919
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2173 SALK AVENUE
STREET 2: SUITE 200
CITY: CARLSBAD
STATE: CA
ZIP: 92008
BUSINESS PHONE: 5105213390
MAIL ADDRESS:
STREET 1: 2173 SALK AVENUE
STREET 2: SUITE 200
CITY: CARLSBAD
STATE: CA
ZIP: 92008
FORMER COMPANY:
FORMER CONFORMED NAME: BIOTIME INC
DATE OF NAME CHANGE: 19930328
4
1
ownership.xml
X0306
4
2022-07-01
0
0000876343
Lineage Cell Therapeutics, Inc.
LCTX
0001278388
BRADSHER NEAL C
C/O BROADWOOD CAPITAL INC.
142 WEST 57TH STREET, 11TH FLOOR
NEW YORK
NY
10019
1
0
1
0
OPTION TO PURCHASE COMMON SHARES
1.57
2022-07-01
4
A
0
50000
0
A
2032-07-01
COMMON SHARES
50000
50000
D
OPTION TO PURCHASE COMMON SHARES
2.86
2031-07-01
COMMON SHARES
50000
50000
D
OPTION TO PURCHASE COMMON SHARES
0.8263
2030-07-01
COMMON SHARES
40000
40000
D
OPTION TO PURCHASE COMMON SHARES
1.03
2029-06-30
COMMON SHARES
40000
40000
D
OPTION TO PURCHASE COMMON SHARES
1.67
2023-06-30
COMMON SHARES
49440
49440
D
These options will vest and become exercisable on July 1, 2023, provided, that Neal C. Bradsher (the "Reporting Person") remains a member of the board of directors of Lineage Cell Therapeutics, Inc. (the "Issuer") on that date.
These options were granted to the Reporting Person by the Issuer on July 1, 2022 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended.
These options are currently exercisable.
/s/ Neal C. Bradsher
2022-07-06